OncRef

Clinical Trial: NCT06738303

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Case Comprehensive Cancer Center
Information Provided By:Case Comprehensive Cancer Center
Last Update Posted:2026-10-02

Study Overview

Brief Summary

The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

Official Title

Carboplatin and Cabazitaxel Versus 177Lu-PSMA-617 in Patients With Aggressive, Metastatic Castrate-resistant Prostate Cancer (CATCH-177)

Conditions

Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

Intervention / Treatment

  • Drug: Cabazitaxel and carboplatin
  • Drug: Lu-PSMA-617

Other Study ID Numbers

  • CASE13824

Start Date (Actual)

2025-07-14

Primary Completion Date (Estimated)

2028-02-20

Study Completion Date (Estimated)

2029-12-01

Enrollment (Estimated)

44

Study Type

Interventional

Phase

Phase 2